Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants.
Khatami A, Snape MD, Ohene-Kena B, Young K, Oeser C, Michaelis LJ, Macleod E, Smee H, Van Der Meeren O, Leyssen M, Caubet M, Yu LM, Heath PT, Faust SN, Finn A, Pollard AJ. Khatami A, et al. Among authors: caubet m. Pediatr Infect Dis J. 2013 Jun;32(6):675-81. doi: 10.1097/INF.0b013e31828672a7. Pediatr Infect Dis J. 2013. PMID: 23348809 Clinical Trial.
Immediate and longer term immunogenicity of a single dose of the combined haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age.
Booy R, Richmond P, Nolan T, McVernon J, Marshall H, Nissen M, Reynolds G, Ziegler JB, Heron L, Lambert S, Caubet M, Mesaros N, Boutriau D. Booy R, et al. Among authors: caubet m. Pediatr Infect Dis J. 2011 Apr;30(4):340-2. doi: 10.1097/INF.0b013e31820013d2. Pediatr Infect Dis J. 2011. PMID: 21068692 Clinical Trial.
Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
Tejedor JC, Merino JM, Moro M, Navarro ML, Espín J, Omeñaca F, García-Sicilia J, Moreno-Pérez D, Ruiz-Contreras J, Centeno F, Barrio F, Cabanillas L, Muro M, Esporrin C, De Torres MJ, Caubet M, Boutriau D, Miller JM, Mesaros N. Tejedor JC, et al. Among authors: caubet m. Pediatr Infect Dis J. 2012 Oct;31(10):1074-7. doi: 10.1097/INF.0b013e318269433a. Pediatr Infect Dis J. 2012. PMID: 22828645 Clinical Trial.
A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
Vesikari T, Forstén A, Desole MG, Ferrera G, Caubet M, Mesaros N, Boutriau D. Vesikari T, et al. Among authors: caubet m. Pediatr Infect Dis J. 2013 May;32(5):521-9. doi: 10.1097/INF.0b013e31827e22e3. Pediatr Infect Dis J. 2013. PMID: 23190785 Clinical Trial.
A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age.
Szenborn L, Czajka H, Brzostek J, Konior R, Caubet M, Ulianov L, Leyssen M. Szenborn L, et al. Among authors: caubet m. Pediatr Infect Dis J. 2013 Jul;32(7):777-85. doi: 10.1097/INF.0b013e31828d6b20. Pediatr Infect Dis J. 2013. PMID: 23838777 Clinical Trial.
Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.
Pauksens K, Nilsson AC, Caubet M, Pascal TG, Van Belle P, Poolman JT, Vandepapelière PG, Verlant V, Vink PE. Pauksens K, et al. Among authors: caubet m. Clin Vaccine Immunol. 2014 May;21(5):651-60. doi: 10.1128/CVI.00807-13. Epub 2014 Mar 5. Clin Vaccine Immunol. 2014. PMID: 24599529 Free PMC article. Clinical Trial.
Persistence clinical studies: can you believe what you see?
Cheuvart B, Bianco V, Caubet M, Douha M, Fissette L, François N, Sumbul A. Cheuvart B, et al. Among authors: caubet m. Hum Vaccin Immunother. 2013 Jun;9(6):1351-7. doi: 10.4161/hv.24168. Epub 2013 Mar 7. Hum Vaccin Immunother. 2013. PMID: 23857273 Free PMC article.
Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults.
Leroux-Roels G, Van Damme P, Haazen W, Shakib S, Caubet M, Aris E, Devaster JM, Peeters M. Leroux-Roels G, et al. Among authors: caubet m. Vaccine. 2016 Jun 8;34(27):3156-3163. doi: 10.1016/j.vaccine.2016.04.051. Epub 2016 Apr 29. Vaccine. 2016. PMID: 27133877 Free article. Clinical Trial.
Erratum to "Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults" [Vaccine 34 (2016) 3156-3163].
Leroux-Roels G, Van Damme P, Haazen W, Shakib S, Caubet M, Aris E, Devaster JM, Peeters M. Leroux-Roels G, et al. Among authors: caubet m. Vaccine. 2017 Oct 9;35(42):5729-5730. doi: 10.1016/j.vaccine.2017.08.076. Epub 2017 Sep 4. Vaccine. 2017. PMID: 28882439 Free article. No abstract available.
Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans.
Burny W, Marchant A, Hervé C, Callegaro A, Caubet M, Fissette L, Gheyle L, Legrand C, Ndour C, Tavares Da Silva F, van der Most R, Willems F, Didierlaurent AM, Yarzabal J; ECR-008 study group. Burny W, et al. Among authors: caubet m. Vaccine. 2019 Mar 28;37(14):2004-2015. doi: 10.1016/j.vaccine.2019.02.015. Epub 2019 Mar 5. Vaccine. 2019. PMID: 30850240 Free article. Clinical Trial.
49 results